Head-to-head evidence
dupilumab vs Rademikibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline
dupilumab · Dupixent
Marketed by Regeneron Pharmaceuticals and partners
NCT01949311 · Phase 3 · completed
This was an explicitly described open-label extension enrolling participants from prior dupilumab atopic dermatitis trials, including the SOLO 1 and SOLO 2 programs, with 2,677 participants receiving dupilumab in a single group. The primary outcomes were safety events rather than a comparative efficacy endpoint, and there was no randomization, blinding, or control arm; therefore, the findings provide limited evidence despite the large enrollment.
Next expected readout: October 2026 · NCT02612454 (registry estimate)
Rademikibart
Developed by Simcere Pharmaceutical and partners
NCT05017480 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 330 participants, with a clinical primary endpoint based on validated Investigator Global Assessment. Although the reported primary response favored rademikibart (29.0% vs 5.9%), the registry does not state whether the primary comparison was statistically significant, so the result remains unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dupilumab's landscape · Rademikibart's landscape